85
Views
6
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for psoriasis

&
Pages 567-596 | Published online: 25 Oct 2006

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Gino A Vena & Nicoletta Cassano. (2007) Anti-tumor necrosis factor therapies for psoriasis. Expert Review of Dermatology 2:3, pages 335-349.
Read now

Articles from other publishers (5)

Andreas Krause, Daniele D'Ambrosio & Jasper Dingemanse. (2018) Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis. Journal of Dermatological Science 89:2, pages 136-145.
Crossref
Richard G. Langley, Kim Papp, Robert Bissonnette, Darryl Toth, Robert Matheson, Micki Hultquist & Barbara White. (2010) Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. International Journal of Dermatology 49:7, pages 818-828.
Crossref
D S Gupta, D Kaul, A J Kanwar & D Parsad. (2009) Psoriasis: crucial role of LXR-α RNomics. Genes & Immunity 11:1, pages 37-44.
Crossref
Robert Bissonnette, Richard G. Langley, Kim Papp, Robert Matheson, Darryl Toth, Micki Hultquist, Gregory P. Geba & Barbara White. (2009) Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. Archives of Dermatological Research 301:6, pages 429-442.
Crossref
Beatrice Passarini, Salvatore Domenico Infusino, Elena Barbieri, Elisa Varotti, Paolo Gionchetti, Fernando Rizzello, Claudia Morselli, Rosy Tambasco & Massimo Campieri. (2007) Cutaneous Manifestations in Inflammatory Bowel Diseases: Eight Cases of Psoriasis Induced by Anti-Tumor-Necrosis-Factor Antibody Therapy. Dermatology 215:4, pages 295-300.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.